A-769662

844499-71-4

C20H12N2O3S

DMSO : 24 mg/mL (66.59 mM; Need ultrasonic and warming)

Epigenetics; PI3K/Akt/mTOR

A-769662 is a potent, reversible AMPK activator with EC₅₀ of 0.8 uM, and has little effect on GPPase/FBPase activity. IC50 & Target: EC50: 0.8 uM (AMPK) In Vitro: A-769662 is equally potent in activating the baculovirus expressed alpha1, beta1, gamma1 recombinant isoform of AMPK (EC₅₀=0.7 uM). A-769662 and A-592107 activate AMPK purified from multiple tissues and species in a dose-responsive manner with modest variations in observed EC₅₀s. EC₅₀s determined for A-769662 using partially purified AMPK extracts from rat heart, rat muscle, or human embryonic kidney cells (HEKs) are 2.2 uM, 1.9 uM, or 1.1 uM, respectively^[1]. A-769662 activates endogenous AMPK in LKB1-expressing (HEK293) and LKB1-deficient (CCL13) cells. A-769662 allosterically activates AMPK complexes containing gamma1 harboring a substitution of arginine residue 298 to glycine (R298G). A-769662 inhibits dephosphorylation of Thr-172 in the mutant gamma1-containing complexes to a similar degree as seen in the wild-type complexes^[2]. A769662 (300 uM) has toxic effects on MEF cells. A769662 reversibly inhibits the proteasomal activity^[3]. In Vivo: A-769662 (30 mg/kg, i.p.) significantly reduced the respiratory exchange ratio (RER) in the SD rat. There are 33% and 58% reductions of malonyl CoA levels in livers of animals treated with 30 mg/kg A-769662 (0.905 nmol/g) or 500 mg/kg metformin (0.574 nmol/g), respectively. A-769662 (30 mg/kg, b.i.d.) significantly decreases fed plasma glucose (30%-40% reduction), while the lower doses (3 and 10 mg/kg) of A-769662 had no effect on the in diabetic ob/ob mice^[1].